Cytokinetics, Incorporated
CYTK
#1825
Rank
$11.011 B
Marketcap
United States
Country
$79.20
Share price
3.60%
Change (1 day)
43.69%
Change (1 year)
Categories
Cytokinetics, Incorporated, a biopharmaceutical company, focuses on discovering, developing, and commercializing novel muscle activators and muscle inhibitors as potential treatments for debilitating diseases in the United States. The company markets MYQORZO, a novel, oral, and small molecule cardiac myosin inhibitor for the treatment of symptomatic oHCM. It also develops Aficamten, a novel, oral, and small molecule…
Key Metrics
Trailing P/E
—
Forward P/E
-15.38
EPS (TTM)
$-7.22
Forward EPS
$-4.45
Price / Book
—
EV / EBITDA
-14.4x
Beta
0.36
Dividend Yield
—
Return on Equity
—
Return on Assets
-28.09%
Debt / Equity
—
Current Ratio
6.66
Gross Margin
0.00%
Operating Margin
-625.95%
Net Profit Margin
0.00%
Free Cash Flow
$-397,408,736
Charts
Price history and financial performance over time.
Price & Market Cap
Aug 19 – Sep 18
-11.92%
Source: Yahoo Finance daily closes. Market cap uses the closest quarterly shares-outstanding filing for each date.
Revenue & Net Income
Annual · USD
RevenueNet Income
Latest Revenue$88.039M
Latest Net Income$-784,955,000
Reporting periods4
Source: Yahoo Finance annual income statements. Year is the fiscal-year end. Most recent period may be trailing-twelve-month (TTM) until the next 10-K is filed.
Compare Cytokinetics, Incorporated with competitors
Side-by-side market cap, revenue, and financial comparison.
Latest News
Latest News
CYTK
No recent news available. Set FINNHUB_API_KEY to enable news.
